BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 21385921)

  • 21. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
    Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
    Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
    Shimizu K; Nishiyama T; Hori Y
    Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
    Wang M; Kern AM; Hülskötter M; Greninger P; Singh A; Pan Y; Chowdhury D; Krause M; Baumann M; Benes CH; Efstathiou JA; Settleman J; Willers H
    Cancer Res; 2014 May; 74(10):2825-34. PubMed ID: 24648348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
    Zhong H; Sanchez C; Spitzer D; Plambeck-Suess S; Gibbs J; Hawkins WG; Denardo D; Gao F; Pufahl RA; Lockhart AC; Xu M; Linehan D; Weber J; Wang-Gillam A
    PLoS One; 2013; 8(10):e77243. PubMed ID: 24130864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
    Brown WS; McDonald PC; Nemirovsky O; Awrey S; Chafe SC; Schaeffer DF; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Cell Rep Med; 2020 Nov; 1(8):100131. PubMed ID: 33294856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
    Sun C; Hobor S; Bertotti A; Zecchin D; Huang S; Galimi F; Cottino F; Prahallad A; Grernrum W; Tzani A; Schlicker A; Wessels LF; Smit EF; Thunnissen E; Halonen P; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Trusolino L; Bernards R
    Cell Rep; 2014 Apr; 7(1):86-93. PubMed ID: 24685132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
    Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
    Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.